In 2012, 143 males and 128 females for every 100,000 ever been diagnosed with lung cancer.
The age-adjusted death rate for lung cancer in the UK is the 11th highest in Europe. Among the 99 countries for which WHO mortality data are available, the UK ranks 15th.
EarlyCDT®-Lung is a blood test that has the ability to help detect cancer before it is visible on the standard CT diagnostic test usually used to find lung cancer. The test measures seven auto-antibodies to aid in the detection of lung cancer earlier and with higher specificity than CT scans:
- The clinically validated blood test for lung cancer measures a panel of 7 autoantibodies associated with small cell and non-small cell lung cancers at all stages of disease
- EarlyCDT-Lung can detect lung cancer up to 4 years earlier than other methods1. Test performance has been optimised for ‘rule-in’ use in conjunction with CT scanning
- EarlyCDT-Lung can be used to assess the malignancy risk of CT-detected pulmonary nodules as a ‘rule-in’ test for lung cancer2,4
- It can also be used in conjunction with CT scanning to ‘rule-in’ and assess the risk of lung cancer in asymptomatic patients at increased risk of the disease3,4,5. It is not a ‘rule-out’ test.
- The test requires a small blood sample either drawn by a phlebotomist or by the patient using a simple finger stick self-draw kit
Lung cancer is usually only detected after symptoms appear, when the cancer is in its latest stages. If lung cancer is detected early, at Stage I or Stage II, survival rates triple.
Please add blood sampling to your order.
85,000 people living in the UK have received a lung cancer diagnosis. This includes people living with the condition, those in remission and those who have been cured.
In 2012, of the 35,419 deaths from lung cancer:
- 7,366 were among those aged 15–64; and
- 28,053 were among those aged 65 and above
The chances of having a current or past diagnosis of lung cancer increase as people get older.
In 2012, only 6 people for every 100,000 had lung cancer among those aged 31–40, rising steadily through 23 per 100,000 among those aged 41–50, peaking at 631 per 100,000 among those aged 71–80, and 666 per 100,000 among those aged 81 and over.
The following Consultants, available for private referrals, know specifically about EarlyCDT-Lung and are familiar with recommended follow-up procedures. Please feel free to use other Consultants as you see fit:
- Prof Sam Janes, Professsor of Respiratory Medicine. (020 7034 8164). Professor Janes is a Consultant in Respiratory Medicine at University College London Hospitals NHS Foundation Trust and the lead clinician for lung cancer across North Central and North East London. He is active in research and is lead investigator on several lung trials.
- Dr Pallav Shah, Consultant Physician in Respiratory Medicine. (020 7351 8021). Dr Shah is the Lead Clinician for lung cancer services at Royal Brompton Hospital and the Chelsea & Westminster Hospital, as well as Honorary Consultant Physician to the Royal Marsden Hospital and the Royal Hospital Chelsea, London.
If your test results shows an elevated list, we will arrange a referral. An additional referral fee applies.
Sources: British Lung Foundation
1 Zhong L, et al., Profiling Tumour-Associated Antibodies for detection of Non-small Cell Lung Cancer J Thor Oncol 2006; 1:513-519
Jett J, et al., Determination of the detection lead time for autoantibody biomarkers in early stage lung cancer using the UKCTOCS cohort. J Thor Oncol 2017; 12(11):S2170
2 For patients with one or more nodules the combined test results ‘Moderate Level’ and ‘High Level’ have Accuracy 83% and PPV 59% (1 in 1.7). For a ‘High Level’ test result: Accuracy 84% and PPV 1 in 1.3 (78%). (Based on lung cancer prevalence of 20%)
3 In asymptomatic patients at increased risk5: Accuracy 92%, PPV 10% (1 in 10); for combined Moderate and High Level results. For a High Level test result Accuracy 97% and PPV 1 in 5 (20%). (Based on lung cancer prevalence of 1.2% increased by a conservative 50% to account for the “look forward” ability for autoantibodies to be detected prior to a cancer being detectable by imaging1)
4 Combined Moderate and High Level test result: Specificity 93%; Sensitivity 41%. High Level test result: Specificity 98% and Sensitivity 28%
5 Increased risk is defined as 20+ pack years and 50+ years, or 40+ years and another risk factor